BioSpace5h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The Hindu26d
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...
Seeking Alpha18h
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
Pharmaceutical Technology12d
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
The American Journal of Managed Care27d
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
In September, the FDA approved the first new schizophrenia treatment in decades. 1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for ...
news10nbc17d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Cobenfy also contains trospium ... to some other countries because of a cumbersome blood testing program. The FDA started the blood tests to watch for the risk of severe neutropenia, a rare ...